ESTRO 2025 - Abstract Book

S3669

Physics - Quality assurance and auditing

ESTRO 2025

Furthermore, we determined the beforementioned complexity metrics on all treatment plans that were clinically delivered on our TrueBeam (Varian) treatment devices in 2023 (N = 1220). This data was projected on the principal components that were derived from the asynchronous sweeping plans. Results: The difference between calculated and measured dose for the sliding gaps range from –0.4% to 6.9%. The dose differences are graphically represented in Figure 2. This figure also shows the first two principal components of the complexity metrics, together with projected data from the clinical plans. The first two principal components describe 93.6% of the total variance of the complexity metrics of the sliding gap plans. All points of the sliding gap plans with a dose deviation >1% are located outside or on the edge of the point cloud that is formed by the clinical plans. In the top-right corner, 15 plans lie outside the commissioned space.